Published in Thromb Haemost on January 12, 2011
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol (2012) 1.53
Direct oral anticoagulants: integration into clinical practice. Postgrad Med J (2014) 1.40
The Prophylaxis of Venous Thromboembolism. Dtsch Arztebl Int (2016) 1.36
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol (2013) 1.17
Deep vein thrombosis: a clinical review. J Blood Med (2011) 1.15
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol (2011) 1.06
Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J (2014) 1.05
New anticoagulants: A concise review. J Trauma Acute Care Surg (2012) 1.04
Direct thrombin inhibitors. Br J Clin Pharmacol (2011) 1.01
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc (2014) 1.00
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. Int Orthop (2011) 0.98
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol (2013) 0.98
Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles? Br J Clin Pharmacol (2012) 0.97
Dabigatran and kidney disease: a bad combination. Clin J Am Soc Nephrol (2013) 0.95
Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol (2014) 0.89
Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting. Biomed Res Int (2014) 0.87
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open (2012) 0.87
The discovery of dabigatran etexilate. Front Pharmacol (2013) 0.86
Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs (2014) 0.86
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc (2013) 0.86
A 12 month review of a modified protocol using low dose Dabigatran Etexilate in postoperative thromboembolic prophylaxis in joint replacement surgery. Thromb J (2012) 0.85
Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty. Can J Surg (2011) 0.85
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert Rev Hematol (2013) 0.84
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag (2013) 0.82
Appropriateness of Dabigatran and Rivaroxaban Prescribing for Hospital Inpatients. Can J Hosp Pharm (2016) 0.79
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. J Arthroplasty (2016) 0.78
Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians. Thrombosis (2013) 0.78
Transitions of care in anticoagulated patients. J Multidiscip Healthc (2013) 0.78
Medical management of venous thromboembolism: what the interventional radiologist needs to know. Semin Intervent Radiol (2012) 0.78
Oral anticoagulants in the management of venous thromboembolism. Nat Rev Cardiol (2013) 0.78
Thromboprophylaxis and orthopaedic surgery: options and current guidelines. Malays J Med Sci (2014) 0.78
Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. Vasc Health Risk Manag (2015) 0.78
Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation. Pharmaceuticals (Basel) (2012) 0.78
Current status of new anticoagulants in the management of venous thromboembolism. Adv Hematol (2012) 0.78
Direct thrombin inhibitors in cardiovascular disease. Nat Rev Cardiol (2012) 0.77
Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences. J Intensive Care (2016) 0.77
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. Vasc Health Risk Manag (2012) 0.76
Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting. Thromb J (2016) 0.76
Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants. Biomed Res Int (2014) 0.76
Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vasc Health Risk Manag (2013) 0.76
The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature. Thromb J (2013) 0.75
Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery. Thromb J (2015) 0.75
New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants. Scientifica (Cairo) (2012) 0.75
Novel oral anticoagulants for venous thromboembolism prophylaxis after total hip or knee replacement: an update on rivaroxaban (xarelto). P T (2013) 0.75
Perioperative management of patients on direct oral anticoagulants. Thromb J (2017) 0.75
More indications approved and safety news for dabigatran etexilate. Maedica (Buchar) (2014) 0.75
New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. World J Orthop (2014) 0.75
New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. Thromb Haemost (2011) 0.75
Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. Cardiol Res (2015) 0.75
Benefits of novel oral anticoagulant agents for thromboprophylaxis after total hip or knee arthroplasty. Am Health Drug Benefits (2012) 0.75
Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials. Thromb J (2015) 0.75
The proof for new oral anticoagulants: clinical trial evidence. Eur Orthop Traumatol (2011) 0.75
The effect of new oral anticoagulants and extended thromboprophylaxis policy on hip and knee arthroplasty outcomes: observational study. Arthroplast Today (2015) 0.75
Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial. ARYA Atheroscler (2014) 0.75
The role of new oral anticoagulants in orthopaedics: an update of recent evidence. Eur J Orthop Surg Traumatol (2017) 0.75
[Prevention of venous thromboembolism in musculoskeletal surgery]. Wien Klin Wochenschr (2014) 0.75
Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. Intern Emerg Med (2017) 0.75
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation (2006) 2.54
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Thromb Haemost (2012) 1.94
Total hip arthroplasty through a minimally invasive anterior surgical approach. J Bone Joint Surg Am (2003) 1.84
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost (2008) 1.64
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol (2005) 1.58
Rotating platform knees: an emerging clinical standard: in the affirmative. J Arthroplasty (2006) 1.58
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin Pharmacokinet (2008) 1.39
Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost (2009) 1.14
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care (2013) 1.14
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol (2014) 1.12
Clinical and biochemical prediction of early fatal outcome following hip fracture in the elderly. Int Orthop (2010) 1.08
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res (2007) 1.08
Total joint replacement in HIV positive patients. J Infect (2008) 1.02
Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica (2003) 1.00
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thromb Res (2012) 0.98
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. Int Orthop (2011) 0.98
Arthroscopic debridement of acute periprosthetic septic arthritis of the knee. Arthroscopy (2005) 0.97
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet (2002) 0.97
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes (2010) 0.96
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost (2009) 0.96
Perioperative mortality in hip fracture patients treated with cemented and uncemented hemiprosthesis: a register study of 11,210 patients. Int Orthop (2013) 0.95
Are critical pathways and implant standardization programs effective in reducing costs in total knee replacement operations? J Am Coll Surg (2007) 0.94
An electronic tool for venous thromboembolism prevention in medical and surgical patients. Haematologica (2006) 0.94
Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor. Expert Rev Cardiovasc Ther (2012) 0.92
Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis. Clin Orthop Relat Res (2012) 0.88
Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW). Int J Stroke (2012) 0.88
Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials. Thromb Res (2012) 0.88
The efficacy and safety of rivaroxaban for venous thromboembolism prophylaxis after total hip and total knee arthroplasty. Thrombosis (2013) 0.87
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost (2007) 0.87
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost (2003) 0.85
Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA. Hip Int (2010) 0.85
Chip with twin anchors for reduced ion suppression and improved mass accuracy in MALDI-TOF mass spectrometry. Anal Chem (2005) 0.84
Tartrate-resistant acid phosphatase 5b (TRAP 5b) as a marker of osteoclast activity in the early phase after cementless total hip replacement. Acta Orthop (2007) 0.83
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thromb Res (2012) 0.82
Prevention of venous thromboembolism after hip or knee arthroplasty: findings from a 2008 survey of US orthopedic surgeons. J Arthroplasty (2011) 0.82
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy. Stroke (2012) 0.81
What's new in total hip arthroplasty. J Bone Joint Surg Am (2013) 0.81
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost (2015) 0.80
The proportion of perioperative mortalities attributed to cemented implantation in hip fracture patients treated by hemiarthroplasty. Hip Int (2014) 0.79
Biochemical lung, liver and kidney markers and early death among elderly following hip fracture. Arch Orthop Trauma Surg (2012) 0.79
Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients. Anticancer Res (2003) 0.79
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis. Thromb Res (2012) 0.79
D-Dimer and prothrombin fragment 1 + 2 in urine and plasma in patients with clinically suspected venous thromboembolism. Blood Coagul Fibrinolysis (2016) 0.79
Thrombin split products (prothrombin fragment 1 + 2) in urine in patients with suspected deep vein thrombosis admitted for radiological verification. Thromb Res (2013) 0.78
The population attributable risk of nutrition and lifestyle on hip fractures. Hip Int (2015) 0.77
Lessons learned from the global orthopaedic registry: study design, current practice patterns, and future directions. Am J Orthop (Belle Mead NJ) (2010) 0.77
Preoperative flexion does not influence postoperative flexion after rotating-platform total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc (2013) 0.77
Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs (2004) 0.77
Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases. Anticancer Res (2005) 0.77
Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res (2008) 0.77
Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty. J Arthroplasty (2013) 0.77
Venous thromboembolism following total knee replacement. J Surg Orthop Adv (2007) 0.77
Total hip arthroplasty in the ankylosed hip. J Am Acad Orthop Surg (2011) 0.77
The infected knee: all my troubles now. J Arthroplasty (2006) 0.76
Comment: low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. Ann Pharmacother (2005) 0.75
Revision total hip arthroplasty using the Zweymuller femoral stem. J Orthop Traumatol (2008) 0.75
Is tartrate-resistant acid phosphatase 5b a potent bio-marker for late stage aseptic implant loosening? Int Orthop (2014) 0.75
New anticoagulants for thromboprophylaxis after total knee arthroplasty. Am J Orthop (Belle Mead NJ) (2013) 0.75
Rate of Improvement in Clinical Outcomes with Anatomic and Reverse Total Shoulder Arthroplasty. J Bone Joint Surg Am (2017) 0.75
Incidence of heterotopic ossification following total hip arthroplasty in patients with prior stroke. Orthopedics (2004) 0.75